03232017Headline:

Asian-Pacific Region to Offer Significant Growth Opportunities for the Sample Preparation Market in the Coming Years

The sample preparation market is witnessing a significant growth and will continue to do so in the next five years. The factors contributing to this growth are the improvements in the funding scenario globally, increase in the number of government sponsored research activities, and developments in drug discovery research. In the forecast period, the Asian-Pacific region is projected to grow at the highest CAGR, with the growth in this region centered at China and India.

The growth of the sample preparation market is likely to be centered at the Asia-Pacific region due to increasing concerns related to the presence of arsenic in food in Japan; government investments in the biomedical and biotechnology industries, development of bioclusters, and outsourcing of clinical research activities in China; increasing government initiatives and growing pharmaceutical industry, growing food security concerns, and advances in personalized medicines in India.

India is witnessing an increase in government initiative and pharmaceutical and biotechnology industry. The Government of India is planning on a major multi-billion dollar initiative with 50% public funding through a public-private partnership (PPP) model to harness India’s innovation capability. Also, the government provides support in terms of setting up world-class infrastructure, creating an internationally competitive scientific manpower for pharma R&D, and supporting venture funding for research in the public and private domain. The government initiatives, expansion of pharmaceutical companies, and improvements in medical infrastructure are some of the major factors driving the demand for sample preparation instruments and kits in India.

China is one of the leading markets for sample preparation products in Asia Pacific region as it provides favorable environment to the market players to operate and invest in the region. For instance, in June 2013, Thermo Fisher Scientific, Inc. (U.S.) invested $9.5 million in its new China Innovation Center in Shanghai. The facility aims to support the company’s growing R&D organization. In addition, the government investments in the biomedical and biotechnology industries, development of bio-clusters, and outsourcing of clinical research activities in China are expected to drive the demand for sample preparation products in the country.

 

What Next?

Related Articles